IL5 and chronic rhinosinusitis with nasal polyps: Mepolizumab, a humanized anti-IL-5 monoclonal antibody, presented an effective add-on treatment option to the standard of care in patients with recurrent, refractory severe CRSwNP and was approved in 2021 by the FDA for this label [13].